Zacks Investment Research·5 days ago
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
MacroGenics, Inc.(MGNX)Earnings, Financials & Key Ratios
MGNX•NASDAQ
$4.75
Price updated Jul 7, 2026
AboutMacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Show more
- Revenue$150M+0.8%
- EBITDA-$66M+36.3%
- Net Income-$75M-11.4%
- EPS (Diluted)-1.18-10.3%
- Gross Margin71.12%-22.5%
- EBITDA Margin-43.93%+36.8%
- Operating Margin-48.72%+34.6%
- Net Margin-49.91%-10.6%
- ROE-86.95%-74.4%
MGNX Price & Volume
MacroGenics, Inc. (MGNX) stock price & volume — 10-year historical chart
Loading chart...
Erratic Milestone Revenue Masks Persistent Operational Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and clinical execution
Key Thesis Takeaways
- MacroGenics faces a precarious financial outlook characterized by extreme revenue volatility, as top-line performance remains tethered to unpredictable collaboration milestones rather than sustainable commercial sales.
- The company's heavy reliance on R&D spending, which frequently exceeds $30 million per quarter, continues to erode the equity base, which has shrunk from $152.6 million in 2023Q4 to just $21.2 million by 2026Q1.
- Investors should remain cautious as the narrowing cash runway and high debt-to-equity ratio of 1.72 suggest an increasing likelihood of dilutive financing to sustain clinical operations.
Verdict Logic
the company's precarious liquidity position, evidenced by a cash balance of only $66.5 million against a quarterly operating loss of $33.4 million, suggests significant risk of future shareholder dilution.
MGNX Growth Metrics
MacroGenics, Inc. (MGNX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years4.01%
5 Years8.87%
3 Years-0.12%
TTM3.05%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-26.06%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-23.6%
Return on Capital
10 Years-46.47%
5 Years-54.19%
3 Years-51.22%
Last Year-34.7%
MGNX Recent Earnings
MacroGenics, Inc. (MGNX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.58-1.8%
$0.57
Rev
$21M+36.3%
$15M
Q2 2026
May 13, 2026Metric
Actual
Est
EPS
$0.58-1.8%
$0.57
Rev
$21M+36.3%
$15M
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.22+47.6%
$0.42
Rev
$41M+19.2%
$35M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.27+156.3%
$0.48
Rev
$73M+161.9%
$28M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.58vs $0.57-1.8% | $21Mvs $15M+36.3% |
| Q2 2026 | May 13, 2026 | $0.58vs $0.57-1.8% | $21Mvs $15M+36.3% |
| Q2 2026 | Mar 9, 2026 | $0.22vs $0.42+47.6% | $41Mvs $35M+19.2% |
| Q4 2025 | Nov 12, 2025 | $0.27vs $0.48+156.3% | $73Mvs $28M+161.9% |
Based on last 12 quarters of dataView full earnings history →
Latest MGNX News
Recent stock market news and headlines for MacroGenics, Inc. (MGNX)
GlobeNewsWire·5 days ago
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora PharmaceuticalsROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced completion of the sale of MacroGenics' good manufacturing practice (GMP) drug substance manufacturing operations to Bora.
GlobeNewsWire·Jun 22, 2026
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® ApprovalROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration's (FDA) accelerated approval of TZIELD® (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). The approval expands the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes.
Peers Comparison
Key metrics vs top competitors for MacroGenics, Inc. (MGNX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.75 | $301.92M | -4.03 | 0.78% | -49.91% | -86.95% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $15.67 | $1.15B | -12.64 | 13.65% | -185.71% | -28.77% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — |
Compare MGNX vs Peers
MacroGenics, Inc. (MGNX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MGNX SEC Filings & Documents
MacroGenics, Inc. (MGNX) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 20, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
May 12, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when MGNX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MGNX Frequently Asked Questions
MacroGenics, Inc. (MGNX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is MacroGenics, Inc.'s revenue?
MacroGenics, Inc. (MGNX) reported $157.1M in revenue for fiscal year 2025. This represents a 234% increase from $47.1M in 2011.
How fast is MacroGenics, Inc. growing?
MacroGenics, Inc. (MGNX) grew revenue by 0.8% over the past year. Growth has been modest.
Is MGNX profitable?
MacroGenics, Inc. (MGNX) reported a net loss of $70.4M for fiscal year 2025.
Dividend & Returns
What is MGNX's return on equity?
MacroGenics, Inc. (MGNX) has a return on equity (ROE) of -86.9%. Negative ROE indicates the company is unprofitable.
What is MacroGenics, Inc.'s free cash flow?
MacroGenics, Inc. (MGNX) had negative free cash flow of $71.7M in fiscal year 2025, likely due to heavy capital investments.